Last reviewed · How we verify

Centre Georges Francois Leclerc — Portfolio Competitive Intelligence Brief

Centre Georges Francois Leclerc pipeline: 0 marketed, 0 filed, 0 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 6 Phase 2 9 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AIO-Studien-gGmbH · 1 shared drug class
  2. Canadian Cancer Trials Group · 1 shared drug class
  3. Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. · 1 shared drug class
  4. French Innovative Leukemia Organisation · 1 shared drug class
  5. GERCOR - Multidisciplinary Oncology Cooperative Group · 1 shared drug class
  6. GlaxoSmithKline · 1 shared drug class
  7. National Research Center for Hematology, Russia · 1 shared drug class
  8. Ospedale Santa Croce-Carle Cuneo · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Centre Georges Francois Leclerc:

Cite this brief

Drug Landscape (2026). Centre Georges Francois Leclerc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centre-georges-francois-leclerc. Accessed 2026-05-16.

Related